Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: A two-panel, two-way, two-period, randomized trial

HIV Medicine

Volumn 14, Issue 7, 2013, Pages 421-429

  Kakuda, Tn ^a   Demasi, R ^a   Van Delft, Y ^b   Mohammed, P ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Janssen Medical Affairs   (Netherlands)

^c Janssen Global Access and Partnership   (United Kingdom)

Author keywords

Artemether; Darunavir; Etravirine; HIV; Lumefantrine; Malaria; Pharmacokinetics

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; ENTEROCOLITIS; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

ARTEMETHER; DARUNAVIR; ETRAVIRINE; HIV; LUMEFANTRINE; MALARIA; PHARMACOKINETICS;

ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; ARTEMISININS; CROSS-OVER STUDIES; DRUG INTERACTIONS; ETHANOLAMINES; FLUORENES; HEALTHY VOLUNTEERS; HIV; HIV INFECTIONS; HUMANS; MALARIA; MIDDLE AGED; PYRIDAZINES; RITONAVIR; SULFONAMIDES;

EID: 84879837326     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12019     Document Type: Article

References (31)

1. UNAIDS. UNAIDS Data Tables 2011. Available at www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2225_UNAIDS_datatables_en.pdf (accessed 1 February 2012).
2. Murray C, Rosenfeld L, Lim S etal. Global malaria mortality between 1980 and 2010: a systematic review. Lancet 2012; 379: 413-431.
3. World Health Organization guidelines for the treatment of malaria, 2nd edn. Available at www.who.int/malaria/publications/atoz/9789241547925/en/index.html (accessed 18 April 2012).
4. Byakika-Kibikwa P, Lamorde M, Mayanja-Kizza H, Khoo S, Merry C, Van Geertruyden JP. Artemether-lumefantrine combination therapy for treatment of uncomplicated malaria: the potential for complex interactions with antiretroviral drugs in HIV-infected individuals. Malaria Research and Treatment 2011, Article ID 703730 (5 pages).
5. Bassat Q. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis 2011; 5: e1325.
6. Novartis Ltd. Riamet 20/120mg tablets. Summary of Product Characteristics. Available at www.medicines.org.uk/emc/medicine/9196/SPC/ (accessed 28 September 2012).
7. Byakika-Kibwika P, Lamorde M, Mayanja-Kizza H, Merry C, Colebunders R, Van Geertruyden JP. Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria. Ther Clin Risk Manag 2009; 5: 1-10.
8. European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe. October 2011. Available at www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41 (accessed 17 October 2011).
9. The Department for Health and Human Services (DHHS). DHHS guidelinesPanel on Antiretroviral Guidelines for Adults and Adolescents. Guidelnes for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. March 2012. Available at http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/37/whats-new-in-the-guidelines- (accessed 5 April 2012).
10. Medecins Sans Frontieres Access Campaign. Medecins Sans Frontieres Access Campaign: untangling the web of antiretroviral price reductions. 14th edn. July 2011. Available at http://utw.msfaccess.org/ (accessed 1 February 2012).
11. Djimimde A, Levevre G. Understanding the pharmacokinetics of Coartem. Malar J 2009; 8 (Suppl 1): S4.
12. Kredo T, Mauff K, Van der Walt JS etal. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 2011; 55: 5616-5623.
13. Byakika-Kibwika P, Lamorde M, Mayito J etal. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 2213-2221.
14. Soyinka J, Onyeji C, Omoruyi S, Owolabi A, Sarma P, Cook J. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009; 61: 439-443.
15. Huang L, Parikh S, Rosenthal PJ etal. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr 2012; 61: 310-316.
16. German P, Parikh S, Lawrence J etal. Lopinavir/ritonavir affects pharmacokinetic exposure of arthemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424-429.
17. Byakika-Kibwika P, Lamorde M, Okaba-Kayom V etal. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 1217-1223.
18. Kredo T, Van der Walt J, Mauff K etal. The interaction between artemether-lumefantrine and ritonavir boosted lopinavir-based antiretroviral therapy in HIV infected people. 19th Conference on Retroviruses and opportunistic infections. Seattle, UK, March 2012 [Abstract 613].
19. Byakika-Kibwika P, Lamorde M, Lwabi P etal. Cardiac conduction safety during coadministration of artemether-lumefantrine and lopinavir/ritonavir in HIV-infected Ugandan adults. Chemother Res Pract. 2011; 2011: 393976.
20. Katlama C, Haubrich R, Lalezari J etal. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-2300.
21. Kakuda T, Wade J, Snoeck E etal. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced patients. Clin Pharmacol Ther 2010; 88: 695-703.
22. Madruga J, Berger D, McMurchie M etal. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized, controlled Phase III trial. Lancet 2007; 370: 49-58.
23. Katlama C, Esposito R, Gatell JM etal. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
24. Haubrich R, Berger D, Chiliade P etal. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11-F18.
25. Cahn P, Fourie J, Grinzstein B etal. Week 48 analysis of once-daily versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1 infected patients. AIDS 2011; 25: 929-939.
26. Schöller-Gyüre M, Kakuda TN, Sekar V etal. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789-796.
27. Fridericia L. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkanken. Acta Med Scand 1920; 53: 469-486.
28. Ortiz R, DeJesus E, Khanlou H etal. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir-ritonavir in treatment naïve HIV-1 infected patients at Week 48. AIDS 2008; 22: 1389-1397.
29. Nsanzabana C, Rosenthal P. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob Agents Chemother 2011; 55: 5073-5077.
30. Martin R, Butterworth A, Gardiner D, Kirk K, McCarthy J, Skinner-Adams T. Saquinavir inhibits the malaria parasite's chloroquine resistance transporter. Antimicrob Agents Chemother 2012; 56: 2283-2289.
31. Achan J, Kahuru A, Iklezi G, Ruel T, Clark T. Charlebois etal. Significant reduction in risk of malaria among HIV+ children receiving lopinavir/ritonavir based ART compared to NNRTI based ART - a randomised, open-label trial. 19th Conference on Retroviruses and opportunistic infections. Seattle, UK, March 2012 [Abstract 26].